ASH: Allogene's off-the-shelf CAR-T posts 60% response rate in fiercely competitive BCMA field

ASH: Allogene's off-the-shelf CAR-T posts 60% response rate in fiercely competitive BCMA field

Source: 
Fierce Biotech
snippet: 

Allogene Therapeutics has linked its off-the-shelf anti-BCMA CAR-T cell therapy to a 60% response rate in a phase 1 trial. The candidate is up against autologous cell therapies that have set the efficacy bar high, but Allogene has off-the-shelf advantages and levers to pull to further improve outcomes.